Copyright
©The Author(s) 2017.
World J Hepatol. Feb 18, 2017; 9(5): 270-277
Published online Feb 18, 2017. doi: 10.4254/wjh.v9.i5.270
Published online Feb 18, 2017. doi: 10.4254/wjh.v9.i5.270
Table 2 Baseline characteristics of 38 carvedilol non responders patients in whom Simvastatin was added
| Parameters | Description |
| Age (mean ± SD) | 58.45 ± 5.95 |
| Gender (male:female) | 21:17 |
| Child-Pugh class (A:B:C) | 14:13:11 |
| Etiology (Alcohol:Viral:NASH or Cryptogenic) | 12:15:11 |
| OesophagealVarices (small:large) | 12:26 |
| Ascites (No:Grade 1:Grade 2:Grade 3) | 21:4:8:5 |
| Total bilirubin (mg/dL) | 2.042 ± 0.77 |
| Serum albumin (mg/dL) | 3.203 ± 0.54 |
| Prothrombin time | 14.105 ± 2.16 |
| International normalized ratio | 1.318 ± 0.15 |
- Citation: Wani ZA, Mohapatra S, Khan AA, Mohapatra A, Yatoo GN. Addition of simvastatin to carvedilol non responders: A new pharmacological therapy for treatment of portal hypertension. World J Hepatol 2017; 9(5): 270-277
- URL: https://www.wjgnet.com/1948-5182/full/v9/i5/270.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i5.270